



Kalydeco® (ivacaftor) – Expanded indication

- On September 25, 2020, [Vertex announced the FDA approval](#) of [Kalydeco \(ivacaftor\)](#), for treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene that is responsive to ivacaftor potentiation based on clinical and/or *in vitro* assay data.
 - Kalydeco was previously approved for this indication in patients 6 months and older.
 - If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a *CFTR* mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
- The approval of Kalydeco for the expanded indication was based on data from a cohort in the 24-week, Phase 3 open-label, safety cohort (ARRIVAL) consisting of 6 children with CF ages 4 months to less than 6 months who have one of 10 mutations in the *CFTR* gene. This cohort demonstrated a safety profile similar to that observed in older children and adults.
- The recommended oral dose of Kalydeco for the treatment of CF in patients 4 months to less than 6 months is one 25 mg packet every 12 hours (total daily dose of 50 mg/day).
 - Refer to the Kalydeco drug label for dosing for pediatric patients 6 months or older and in adult patients.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.